Skip to main content
Risk of Herpes zoster from upadacitinib RCTs: UPA > ADA > ADA+MTX > MTX. 5306 RA pts, HZ/100 Pt-Yrs was 0.8 MTX mono; 1.1 ADA+MTX; 3.0 UPA 15 mg and 5.3 UPA 30 mg. 71% of UP HZ cases involved a single dermatome. Higher risk w/ prior HZ & Asians https://t.co/0QUvXmFrJ3

Dr. John Cush @RheumNow( View Tweet )

Oct 18, 2021

RheumNow Podcast – Quackademia (10.15.2021)

Oct 14, 2021

Dr. Jack Cush reviews the FDA approvals, news and the latest journal articles from the past week on RheumNow.com.

Read Article
NICE issued a positive final appraisal recommending upadacitinib in previously treated moderate active rheumatoid arthritis (RA). This will expand UPA use to nearly 27,000 RA patients in the UK. Final pub date is Nov 10, 2021 https://t.co/A8OuzNlrAz

Dr. John Cush @RheumNow( View Tweet )

Oct 14, 2021
Upadacitinib was shown to be effective in two Phase 3 SELECT-AXIS trials. 1st trial: in bDMARD-IR AS pts the ASDAS resp was 44% vs 10% PBO at wk 14). 2nd trial: in nr-axSpA, the ASDAS response at wk 14: 42% vs 18% PBO. https://t.co/rnv9VVITeE

Dr. John Cush @RheumNow( View Tweet )

Oct 12, 2021
Deucravacitinib (oral TYK2 inhibitor) in development, has been shown to be highly effective in psoriasis & PsA, but failed to meet its primary endpoints at wk 12 (remission) in Ulcerative Colitis in the phase 2 LATTICE-UC trial vs placebo https://t.co/ZGYuozFgOk

Dr. John Cush @RheumNow( View Tweet )

Oct 11, 2021
ICYMI: Upadacitinib RA program (5306 pts) the risk of H. zoster by Rx and dose (HZ/100PYs) MTX = 0.8/100PY ADA+MTX= 1.1/100PY UPA 15 mg= 3.0/100PY UPA 30 mg = 5.3/100PY Hence there is a 4-5X risk of HZ w/ JAKinhibitors https://t.co/wo9ih5PJ77 #RheumNow https://t.co/h1GoGzADdv
Dr. John Cush @RheumNow( View Tweet )
Oct 10, 2021

RheumNow Podcast – #ACA: Ask Cush Anything (10.8.2021)

Oct 08, 2021

Arthritis numbers are rising, and people are finally talking about osteoarthritis. Also, ACR 2021 is just a few weeks away - are you ready? Finally, I'll review cases and questions submitted by viewers in Ask Cush Anything (#ACA). This, and nearly a dozen news items and reports, are discussed in

Read Article
MEDWATCH (FAERS) data on venous thromboembolic (VTE) risk with JAK inhibitors from 2010-2019 https://t.co/oKkTYcRsxL

Dr. John Cush @RheumNow( View Tweet )

Oct 07, 2021

Pathways to a Psoriatic Arthritis Diagnosis

Oct 06, 2021

Ogdie and colleagues have retrospectively analyzed a longitudinal cohort of psoriatic arthritis (PsA) patients, showing that only two-thirds of PsA are diagnosed by rheumatologists, PCPs and dermatologists, with significant differences in what preemptive symptoms were noted by different

Read Article
ICYMI: JAK inhibitors as potential treatment for Juvenile Dermatomyositis: nice review of the biology of JAKi effects and the reports of JAKi success in adults and kids with IIM https://t.co/k3qunsCdBN https://t.co/nyqMo6vh88
Dr. John Cush @RheumNow( View Tweet )
Oct 03, 2021

RheumNow Podcast – Jack of All Subspecialties (10.1.2021)

Oct 01, 2021

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com




  1. A population based Swedish study of birth records shows that antibiotic exposure in first three years of life to be associated with a future risk of JIA, although infections during fetal

Read Article

RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)

Sep 23, 2021

Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVID

Read Article
JAKi vs bDMARDS in Real World Data https://t.co/7P6zvp45vH

Dr. John Cush @RheumNow( View Tweet )

Sep 23, 2021
FDA approves Jakafi for chronic GVHD. Ruxolitinib (Jakafi, Incyte), an oral Janus kinase 1/2 inhibitor, previously received approval for treatment of patients aged 12 years or older with steroid-refractory acute GVHD. https://t.co/isItDebNZ8

Dr. John Cush @RheumNow( View Tweet )

Sep 22, 2021
Regarding Pfizer 1133 tofacitinib Safety study and recent FDA JAKi warnings -- Dr. Roy Fleischmann has said, "“There is a small increase in risk,” “But is it clinically meaningful?”, Read full interview here https://t.co/2Wd5h69Dfq

Dr. John Cush @RheumNow( View Tweet )

Sep 21, 2021
Metanalysis of JAK inhibition (tofacitinib & ruxolitinib) in alopecia areata - 12 studies, 346 Pts, Rx success (using SALT50 resp) was 66%, not influenced by age, sex, subtype. Alopecia recurrence seen w/in 3 mos of JAK D/C (in74%) https://t.co/CBSy4Kci80

Dr. John Cush @RheumNow( View Tweet )

Sep 16, 2021
Popular read— FDA: New Cardiac and Cancer Warnings for All JAK Inhibitors https://t.co/jayl8ufPHn

Dr. John Cush @RheumNow( View Tweet )

Sep 16, 2021

High Drug Switching and Low Persistence in Rheumatoid Arthritis

Sep 13, 2021

Mease and colleagues have catalogued the current practices assessed in the CORRONA registry, noting that increased DMARD switching and decreased time on a given therapy by US physicians.



This retrospective analysis assessed treatment patterns among patients newly initiated on biologic

Read Article

ACR Comments on JAK Inhibitors and FDA Announcement

ACR
Sep 13, 2021

Following is a statement from ACR President David Karp, MD, PhD, on JAK inhibitors and FDA drug safety communication.

Read Article

RheumNow Podcast – High Science and Future Treatments (9.10.2021)

Sep 10, 2021

This week: high science that affect future treatments; breakthrough infections in our patients, and what's up with that; and soon your radiologist is going to be replaced by AI. This and more in our review of the news and journal articles from the past week.

Read Article
Dr. Cush is joined by rheumatology colleagues to discuss impressions and impact of the 9/1/21 FDA Drug Safety Communication to physicians regarding new label changes. #RheumNow https://t.co/F37SCpJnsW https://t.co/uhdOjFo0yP
Dr. John Cush @RheumNow( View Tweet )
Sep 08, 2021
FDA JAKi Warnings, 2nd Panel of rheumatologists weigh in on this. Drs. Cush, Dao, Tate, Sparks, Shergy. https://t.co/eETzP8DspC via @YouTube #RheumNow @KDAO2011 @uptoTate @jeffsparks @WilliamShergy https://t.co/iqxFQjJQ0l
Dr. John Cush @RheumNow( View Tweet )
Sep 06, 2021
ICYMI: FDA slaps new BOXED warning revision on ALL JAK inhibitors (Xeljanz, Olumiant, Rinvoq) after final revew of the Pfizer Oral Surveillance study. New warnings for incr risk of MI, CVA, VTE, lymphoma & death see w/ BOTH dose of tofacitinib. https://t.co/tvTv40oy59

Dr. John Cush @RheumNow( View Tweet )

Sep 04, 2021
FDA JAK inhibitor warnings and what it means (also: what do you think?); other news released this week; and, two questions submitted from listeners. Dr. Cush discusses this and more in this week's podcast. https://t.co/4jTBhYDzRn https://t.co/lMpl2IOeXe
Dr. John Cush @RheumNow( View Tweet )
Sep 03, 2021

Expert Panel: Initial Views on FDA Warnings for JAK Inhibitors

Sep 02, 2021

Dr. Jack Cush is joined by Drs. Roy Fleischmann (Dallas), Allan Gibofsky (NYC), and Artie Kavanaugh (San Diego) to discuss the 9/2/21 FDA Drug Safety Communication regarding the cardiovascular and cancer risks arising from the Pfizer 1133 (ORAL Surveillance) tofacitinib study, but also applied

Read Article
×